This week on the Readout LOUD
Can an AI tool be better than the industry standard at predicting which cancer patients will respond to treatment? Will drug companies feel the impacts of new cuts at the Department of Health and Human Services? And what will happen to all of the consumer health data owned by 23andMe? We discuss all that and more on this week's episode of "The Readout LOUD," STAT's biotech podcast. Adam, Elaine, and Allison discuss the Trump administration's plan for huge job cuts and a restructuring of the country's top health care agencies, the approval of the first drug to treat a devastating rare disease, and the bankruptcy of 23andMe. Then, we bring on the chief executive of startup Altis Labs to discuss new data from a study they conducted with AstraZeneca on an AI tool for cancer drug development. Listen Now For more on the HHS cuts, go here; To read more about Soleno Therapeutics' Prader-Willi drug, go here; For Matt's take on the 23andMe bankruptcy, go here; and for more on Altis' AI model, go here. Subscribe to the podcast on Apple Podcasts or Spotify to never miss an episode Visit the archive to see past episodes |
|
| STAT, 1 Exchange Place, Boston, MA | ©2025, All Rights Reserved. | |
|
No comments